Arcus Biosciences Reveals Positive Data from Terminated TIGIT Combo Trial, Supporting Future Development

Positive Data from Terminated Trial:
Arcus Biosciences has disclosed positive data from the terminated ARC-10 study, which evaluated the combination of domvanalimab (anti-TIGIT) and zimberelimab (anti-PD-1) in cancer treatment.

Risk Reduction:
The combination therapy reduced the risk of death by 36% compared to zimberelimab alone at a median follow-up in the 98-subject ARC-10 study.

Future Development:
The positive data supports Arcus's decision to continue developing the TIGIT combo, despite the termination of the ARC-10 study.

Ongoing Phase 3 Study:
The data also supports the ongoing Phase 3 STAR-221 study, which is evaluating the same combination therapy for upper GI cancers.

Potential Market Impact:
The combination could potentially be the first anti-TIGIT combination to market for upper GI cancers, addressing a high unmet need.